1 asset in SMARCB1-Deficient Kidney Medullary Carcinoma
Therapeutic assets addressing SMARCB1-Deficient Kidney Medullary Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
Adriamycin SMARCB1-Deficient Kidney Medullary Carcinoma | M.D. Anderson Cancer Center | P2 | CCC (53) |